The technology in question, an isolated aseptic fill and finish line, will be installed at the 70,000 sq ft drug production facility in Billerica, Massachusetts that Pharmalucence started work on this time last year.
In addition to providing the technology, Germany-based Bosch will also help with Pharmalucence implementation, which is due to be delivered sometime next year and available for commercial scale production early in 2013.
Miroslav Horvat, sales manager at Bosch’s Product Division Pharma Liquid said: “Upon completion, Pharmalucence will offer New England's first advanced barrier isolated aseptic fill and finish facility operating in the contract manufacturing market.
This was echoed by Pharmalucence CEO said the investment will “help us achieve the highest level of sterility assurance and regulatory compliance for our products and for those of our contract manufacturing clients.
Pharmalucence makes radiopharmaceuticals for a variety of diagnostic and imaging applications, supplying clients like UPPI, Cardinal Health, Covidien, GE, Lantheus Medical Imaging.
The firm also provides contract manufacturing services using its excess manufacturing capacity, which is an area of its business it has sought to expand in recent years.
Bosch did not respond to requests for additional information ahead of publication.
News of the deal marks something of a change for the Germany firm whose recent announcements have concerned acquisitions it has made in the processing technology sector.
In April for example Bosch bought drying and granulation specialistManesty and tabletting tech firm Huttlin from rival technology supplier Oystar, which has been refocusing on its secondary packaging business.